Novo Nordisk Korea has signed a strategic memorandum of understanding (MOU) with Seoul National University Hospital (SNUH) on Tuesday to expand domestic participation in global clinical trials. 

The signing ceremony, held at SNUH, was attended by Kim Yong-jin, president of the Biomedical Research Institute at SNUH, and Sasha Semienchuk, General Manager of Novo Nordisk Korea.

This marks the second strategic partnership Novo Nordisk Korea has established with a domestic clinical trial institution this year. The company aims to provide more opportunities for Korean patients with chronic diseases to participate in global trials and strengthen Korea’s role in developing innovative medicines.

The collaboration with SNUH will focus on global clinical trials and real-world studies in diabetes, obesity, and rare diseases, with plans to expand into other chronic conditions in the future.

Kim emphasized the partnership’s significance, noting, “It is meaningful for SNUH, a leader in medical advancements, to collaborate with Novo Nordisk, a pioneer in chronic disease treatment for over a century. I hope this synergy contributes to a healthier future for patients in Korea.”

Semienchuk highlighted the importance of the agreement, saying, “This partnership not only broadens opportunities for Korean patients to join global clinical trials but also strengthens our collaboration in developing treatments for chronic diseases."